Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2021-01-20 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
关于2020年度业绩预告的公告
Earnings Release Classification · 95% confidence The document is titled '2020 年度业绩预告' which translates to '2020 Annual Performance Forecast'. It provides preliminary financial estimates for the fiscal year 2020, including expected revenue, net profit, and R&D expenses. It explicitly states that the data is preliminary and unaudited, and that the final audited financial data will be disclosed in the formal 2020 annual report. The document is relatively short (1689 characters) and serves as a forecast or earnings guidance rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. Therefore, the correct classification is Earnings Release (ER). FY 2020
2021-01-20 Chinese
瑞银证券有限责任公司关于前沿生物药业（南京）股份有限公司2020年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is a detailed onsite inspection report by a sponsoring securities company (瑞银证券有限责任公司) regarding the continuous supervision work for the year 2020 of a listed company (前沿生物药业（南京）股份有限公司). It covers governance, internal control, information disclosure, independence, use of raised funds, related party transactions, guarantees, major investments, and operational status. The document is a formal report of the inspection findings rather than an announcement or a brief summary. It is not an annual report, audit report, or earnings release, but a regulatory compliance and supervision report by the sponsor. This type of document fits best under Audit Report / Information (AR) as it is a standalone audit/inspection report related to regulatory compliance and internal controls, not a full annual report or other category. The document length is 2699 characters, which is short but the content is substantive and detailed, not a mere announcement or certification. Therefore, the classification is AR with high confidence. FY 2020
2021-01-08 Chinese
关于公司产品注射用艾博韦泰新纳入国家医保目录的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the inclusion of a product (injection drug) into the national medical insurance catalog. It contains no financial statements or detailed financial performance data, but rather describes product and regulatory information, impact on the company, and risk warnings. The document length is short (1594 characters) and it is an announcement about a product and regulatory update, not a financial report or earnings release. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-12-28 Chinese
关于董事会秘书辞职及聘任副总经理兼董事会秘书的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the current board secretary and the appointment of a new deputy general manager who will also serve as the board secretary. It includes details about the qualifications of the new appointee and compliance with relevant laws and stock exchange rules. There is no financial data, earnings information, or report publication mentioned. The content clearly relates to changes in the company's board or senior management positions. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, not a report or announcement of a report publication.
2020-12-25 Chinese
独立董事关于第二届董事会第十六次会议审议相关事宜的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the appointment of a deputy general manager and board secretary. It references compliance with company laws, articles of association, and board rules. The content focuses on board/management personnel changes and approvals rather than financial results, audit, or other report types. The document length is short (630 characters) and contains no financial data or report attachments. Therefore, it fits best under Board/Management Information (MANG).
2020-12-25 Chinese
瑞银证券有限责任公司关于前沿生物药业（南京）股份有限公司募投项目金额调整及使用募集资金置换预先投入自筹资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company (瑞银证券) regarding the adjustment of the amount of funds raised for investment projects and the use of raised funds to replace previously self-raised funds invested by the company. It references regulatory guidelines related to the management and use of raised funds, details the amounts raised, adjustments to investment projects, and includes an auditor's verification report. The document is not a full annual or interim financial report, nor is it a simple announcement. It is a specialized audit/verification report related to fundraising and use of proceeds, which fits the category of Audit Report / Information (AR). The document length (4827 characters) and content confirm it is a substantive report, not just an announcement or certification letter.
2020-11-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.